FAQ · safety and regulatory record
CJC-1295: frequently asked questions, answered from the record
Direct answers on the safety profile, the regulatory status, the side-effect literature, and the questions people most often ask about CJC-1295 — each cited where it makes a quantitative claim.
Reported and Theoretical Side Effects of CJC-1295
The reported and theoretical side effects of CJC-1295 are mostly extrapolated from growth-hormone-axis stimulation generally, because controlled side-effect data specific to CJC-1295 in healthy adults are lacking. The concerns that recur in the literature are fluid retention and edema — growth hormone increases renal sodium reabsorption — and effects on insulin sensitivity, alongside the epidemiologic concern that sustained IGF-1 elevation is associated with a modestly increased risk of certain cancers [11].
That IGF-1 concern is not abstract for this compound specifically: the DAC variant kept IGF-1 elevated up to 28 days after repeat dosing [1], so the sustained-elevation profile the epidemiology worries about is exactly what the long-acting form produces. The FDA also cited immunogenicity and other safety concerns for growth-hormone secretagogues, including CJC-1295, in briefing materials for the 2024 Pharmacy Compounding Advisory Committee [1]. None of this is a controlled safety dataset; it is the honest perimeter of what is known and what is plausibly concerning.